Kenneth Pittman
Child & Adolescent Psychiatry · Chattanooga, TNNPI 1588822431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,891 of the $152,054 with a category attached, or 77.5%. 17 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 48.9% of the total. 2025 is the largest year on record at $71,148, 7.5 times the $9,459 reported in 2019. Among child & adolescent psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 688 payments — averaging $221.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$74K
- Collegium Pharmaceutical, Inc.$37K
- Tris Pharma Inc$17K
- Corium, LLC$11K
- Ironshore Pharmaceuticals Inc.$10K
- Sunovion Pharmaceuticals Inc.$450
- plus $1K from 11 others
What the payments were for
- Consulting fees$6,6904%
- Speaking & faculty fees$117,89178%
- Travel & lodging$14,46110%
- Food & beverage$12,9929%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 206 | $74,345 |
| Collegium Pharmaceutical, Inc. | 60 | $37,339 |
| Tris Pharma Inc | 95 | $17,201 |
| Corium, LLC | 99 | $10,931 |
| Ironshore Pharmaceuticals Inc. | 114 | $10,433 |
| Sunovion Pharmaceuticals Inc. | 29 | $450 |
| Neos Therapeutics, LP | 29 | $400 |
| Otsuka America Pharmaceutical, Inc. | 17 | $289 |
| Arbor Pharmaceuticals, Inc. | 10 | $145 |
| Adlon Therapeutics L.p. | 6 | $92 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $76 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Noven Therapeutics, LLC | 3 | $66 |
| Shire North American Group Inc | 4 | $52 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Avion Pharmaceuticals | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$70,364
- JORNAY PM$45,811
- Dyanavel XR$15,679
- Azstarys$8,915
- Quillichew ER$8,686
- Quillivant$7,036
- Quillivant XR$1,650
- Jornay PM 20mg capsules (Bottle of 100)$132
How this compares
$152,054 in reported general payments places this provider in the 95th percentile of 43 child & adolescent psychiatry providers in Tennessee.
See all child & adolescent psychiatry providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,838 |
| Lisdexamfetamine Dimesylate | 36 | $5,280 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 139 | $3,957 |
| Methylphenidate ErMethylphenidate Hcl | 53 | $3,491 |
| Oxtellar XrOxcarbazepine | 13 | $3,210 |
| Paliperidone ErPaliperidone | 20 | $3,005 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 11 | $2,890 |
| Methylphenidate | 11 | $2,503 |
| Methylphenidate Er (La)Methylphenidate Hcl | 12 | $1,465 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $1,404 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 40 | $1,399 |
| Aripiprazole | 55 | $1,029 |
| Escitalopram Oxalate | 30 | $597 |
| Methylphenidate Hcl | 40 | $464 |
| Haloperidol | 13 | $394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $76 | $9,83826 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $74,345 | $3,21013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 child & adolescent psychiatry providers in Tennessee.
Other child & adolescent psychiatry in Chattanooga
- Cassandra SimmsChattanooga$5K
- Vijayalakshmi AppareddyChattanooga$237
- Susan McGuireChattanooga$108
- Marie BeasleyChattanooga$14
- Valerie ArnoldMemphis$43K
- David StrubleMemphis$4K
- David PatzerNashville$4K
- Caryn StollerKnoxville$2K
- Allyson CundiffNashville$2K
- Kevin SandersNashville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.